Stock Market Update - July 31, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. FCUV - Focus Universal Inc.
Price: $11.6 | Change: +517.02% ($9.72)
FCUV surged by an incredible 517.02%, primarily fueled by the launch of its new Deterministic AI Forms Auto-Populate Engine on July 31, 2026. This intelligent instrumentation platform maker introduced an AI platform designed to automate business document processing, transforming repetitive manual tasks into autonomous electronic workflows.
The software's standout feature is its ability to identify, extract, validate, and transfer data from various business records—such as invoices and contracts—into completed forms, all without requiring templates, coding, or workflow programming. It even handles 24/7 batch processing for large document volumes. A few days earlier, FCUV also commenced its e-commerce operations, adding to overall positive investor sentiment.
This new product significantly expands Focus Universal's Deterministic AI technology portfolio into broader business automation. The market's strong reaction underscores the growing interest in practical, no-code AI solutions that promise to streamline enterprise operations and boost efficiency.
2. WETO - Wetour Robotics Limited
Price: $0.09 | Change: +200.00% ($0.06)
WETO:NASDAQ just saw an impressive 200.00% gain, catching investor attention. This significant upward movement is primarily in anticipation of a 1-for-100 reverse stock split, effective August 3, 2026. This corporate action mechanically consolidates 100 existing shares into one new share, boosting the per-share price—often to help a company meet exchange minimum bid price requirements and improve its marketability. It's important to remember this doesn't change the company's overall market value.
Adding to the buzz, Wetour Robotics also announced several positive developments. These include a definitive 24-month commercial agreement in North America with an international logistics company, potentially worth up to US$20 million. The company also joined the Qualcomm Partner Network for its industrial AI initiatives and showcased its Orchestra platform for wearable robotics, powered by NVIDIA Jetson.
What makes WETO's recent surge interesting is this dual catalyst: a strategic corporate move to boost its share price for compliance, combined with actual business traction in the growing fields of robotics and AI. This blend of corporate strategy and operational progress is what's driving the current excitement.
3. FMFC - Kandal M Venture Limited
Price: $0.5241 | Change: +141.41% ($0.307)
FMFC:NASDAQ saw an impressive 141.41% gain recently, capturing significant attention. This surge is primarily attributed to the company's strong fiscal year 2026 financial results and a new growth capital facility. Kandal M Venture reported a 12.4% increase in net income, largely due to reduced interest expenses and disciplined cost control, even as revenues remained steady.
A key catalyst was the recently secured $25 million growth capital facility, with $1 million already put to use. These funds are specifically allocated for equipment and technology upgrades at Kandal's manufacturing plants in Cambodia and the Philippines. This strategic investment aims to scale factory output significantly, preparing the company to meet a verified mid-double-digit increase in customer orders from its international fashion brand clients.
Essentially, FMFC is investing to build a more resilient, tech-enabled manufacturing platform across multiple countries. This move is designed to enhance its supply chain and position it strongly for anticipated demand from both existing and new customers in Europe and Asia.
4. REPL - Replimune Group, Inc.
Price: $11.2 | Change: +107.02% ($5.79)
REPL saw its stock price rocket over 107% around August 1, 2026.
This massive jump was sparked by a highly positive vote from a U.S. Food and Drug Administration (FDA) advisory committee. On July 30, 2026, the committee overwhelmingly supported Replimune's lead investigational drug, RP1, confirming its efficacy results for advanced melanoma patients were evaluable and clinically meaningful. This crucial endorsement significantly boosts the chances of RP1 receiving final FDA approval soon.
What makes this particularly noteworthy is that the advisory committee's positive stance represents a major reversal, overcoming previous FDA concerns that had led to prior rejections. With the final FDA decision expected by August 2, 2026, the market is now much more optimistic about RP1's future and Replimune's prospects.
5. MGRX - Mangoceuticals, Inc.
Price: $0.5571 | Change: +89.75% ($0.2635)
MGRX skyrocketed an impressive 89.75% around August 1, 2026! This significant surge came after Mangoceuticals, a company previously focused on health and wellness, announced a definitive business combination agreement with Nuclea Energy Inc. This strategic move is set to completely transform MGRX, effectively pivoting it into the advanced nuclear technology sector.
Nuclea Energy is an innovative company developing the Morpheus microreactor, a lead-cooled, factory-built micro-modular reactor. The merger is designed to provide Nuclea with a Nasdaq public listing, enhancing its access to capital for developing and commercializing this cutting-edge microreactor technology. News of this dramatic shift in focus led to MGRX shares jumping significantly.
What makes this development particularly noteworthy is its alignment with current market trends. There's an accelerating demand for reliable, carbon-free electricity, driven largely by the massive growth of AI infrastructure and data centers. This strategic repositioning could see the 'new' MGRX aiming to capitalize on this critical and expanding energy need.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.